October 16, 2023

Deciphex Secures €10m Venture Debt Financing to Accelerate Digital Pathology and AI Services Expansion

DUBLIN, IRELAND — October 16th 2023 —Deciphex, a trailblazer in digital pathology solutions, is delighted to announce a successful €10m venture debt financing round. This strategic investment will fuel the company's capacity growth, headcount increase, service enhancement, and expansion to new markets, addressing the growing global demand in pathology services.

Founder and CEO of Deciphex, Donal O’Shea, expressed his enthusiasm:

“This financing is a pivotal step for us in our mission to transform pathology through digital innovation. It will enable us to empower more pathologists, improve service delivery, and contribute significantly to enhanced patient care and expedited drug development.”

David Bateman, Senior Partner at Claret Capital Partners, remarked:

“We are confident that our investment in Deciphex will have far-reaching impacts on the future of digital pathology. The company’s relentless dedication to innovation and excellence, and its unique approach to leveraging AI, position it at the forefront of the industry. We look forward to supporting Deciphex as it continues to break new ground and set new standards in pathology services.”
Picutre of Donal O'Shea - CEO of Deciphex
Donal O'Shea - CEO of Deciphex

Addressing the Pathology Crunch Point

Pathology is a crucial component of health service delivery, impacting 95% of clinical care pathways, and is vital in ensuring the safety and efficacy of new drugs in development. The increasing test volumes, complexity, and declining pathologist numbers are contributing to a developing crunch point in global pathology services. Deciphex stands at the forefront of addressing this challenge, networking pathologists globally, and incorporating AI to drive efficient and high-quality reporting.

Innovative Platforms for Pathology

Deciphex's platforms, Diagnexia and Patholytix, are revolutionizing the field. Diagnexia provides on-demand access to remote subspecialty pathologists for primary diagnostics and secondary consult services, while Patholytix offers an industry-leading digital pathology workflow & integrated AI platform for Research Pathology, trusted by leading CROs and pharmaceutical companies.

About Deciphex

Deciphex is a pioneering leader in digital pathology, committed to addressing the growing global demand in pathology, and integrate AI driving efficient, high-quality reporting, enhancing patient care, and accelerating drug development. With a diverse and experienced team and cutting-edge platforms like Diagnexia and Patholytix, Deciphex is set to redefine the future of pathology.

Contact:

Katie Higgins
Marketing Manager

Email: katie.higgins@deciphex.com
Phone: +353 1 221 0842

Deciphex
DCU Alpha Building, Innovation Campus,
11 Old Finglas Rd, Glasnevin, Co. Dublin, D11 KXN4.
Call: +353 1 582 7193
Email: Info@deciphex.com
Twitter: @deciphex

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.
return to news

Contact Details

Invent Buidling at DCU

Ireland

Deciphex
DCU Alpha Building, Innovation Campus,
11 Old Finglas Rd, Glasnevin, Co. Dublin
D11 KXN4

Call: +353 1 582 7193

Email: Info@deciphex.com

Twitter: @deciphex

USA Headquarters Building

USA

Deciphex Inc.
1012 95th Street, Naperville,
Chicago, Illinois
60564

Call: +1 708 573 0674

Email: info@deciphex.com

USA Headquarters Building

UK

Diagnexia
Exeter Science Park Centre,
6 Babbage Way, Exeter
EX5 2FN

Call: +44 1 29730 2245

Email: Info@deciphex.com

Email Us

The details you submit will be used so that we can contact you in relation to your query either by email or your preferred method of contact. Read our privacy policy here.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form
Copyright Deciphex 2021
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.